Clinical trial · Interventional
GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors
Spatially Fractionated Radiation (SFR) Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| spatially fractionated radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- GRID radiation therapy
- description
- A single dose of 15-20Gys of spatially fractionated radiation therapy
- interventionNames
- Radiation: spatially fractionated radiation therapy
Primary outcomes (1)
- measure
- Symptom relief, as measured using the CTCAE grading system (v4.0) and pain questionnaire
- timeFrame
- 3 months post treatment
Secondary outcomes (4)
- measure
- Acute toxicity of treatment, as measured using the CTCAE grading system (v4.0)
- timeFrame
- 1 week
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible. * Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation * Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis * WHO performance status of 0-2 * Aged 18 years or older * Ability to sign and understand an informed consent form Exclusion Criteria: * Potentially curable patient * Previous palliative radiation with hypofractionation * Tumor located near the spinal cord or in the brain * Pregnant or nursing woman
References
Publications (0)
Data not yet available